IP Library › Granted Patent US 11,104,715
Granted Patent B2
US 11,104,715 · App. 16/996,030 · Granted Aug 31, 2021

Methods for producing aflibercept in chemically defined media having reduced aflibercept variants

Inventors: Shawn Lawrence (Nyack, NY); Amy Johnson (Briarcliff Manor, NY); Meghan Casey (Ringwood, NJ); Jaimie Mastrogiacomo (White Plains, NY); Shunhai Wang (Ossining, NY); Ning Li (New Canaan, CT)
Assignee: Regeneran Pharmaceuticals, Inc.
C07K14/71C12P21/02C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,104,715
App. No.
16/996,030
Granted
Aug 31, 2021
Kind
B2
Abstract

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Claims (53)

1. A method of producing aflibercept harvested from a host cell cultured in a chemically defined medium (CDM), comprising:

(a) providing a host cell genetically engineered to express aflibercept;

(b) culturing said host cell in said CDM under conditions suitable in which said host cell expresses said aflibercept wherein the cumulative concentration of nickel in said CDM is less than or equal to 0.4 μM or about 0.4 μM and one or more of the following:

i. the cumulative concentration of iron in said CDM is less than or equal to 55.0 μM;

ii. the cumulative concentration of copper in said CDM is less than or equal to 0.8 μM;

iii. the cumulative concentration of zinc in said CDM is less than or equal to 56.0 μM;

iv. the cumulative concentration of cysteine in said CDM is less than or equal to 10.0 mM, and

v. said CDM includes anti-oxidants where the cumulative concentration of an antioxidant is about 0.001 mM to about 10.0 mM for any single anti-oxidant; and

(c) harvesting aflibercept produced by said host cell.

2. The method of claim 1 , wherein said harvest has a color no more yellow-brown than European Color Standard BY2, wherein the aflibercept concentration is 5.0 g/L.

3. The method of claim 2 , wherein said anti-oxidants are taurine, hypotaurine, glycine, thioctic acid, glutathione, choline, hydrocortisone, Vitamin C, Vitamin E or combinations thereof.

4. The method of claim 2 , wherein said cumulative concentration of an anti-oxidant in said CDM is about 0.001 mM to about 10.0 mM for any single anti-oxidant and the cumulative concentration of all anti-oxidants is about 30.0 mM or less than 30.0 mM.

5. The method of claim 1 , wherein aflibercept titer, viable cell concentration, viability, ammonia or osmolality is substantially unchanged.

6. The method of claim 1 , wherein said host cell is selected from the group consisting of CHO, NS0, Sp2/0, embryonic kidney cell and BHK.

7. The method of claim 1 , wherein said harvest comprises one or more aflibercept variants, wherein said variants have at least one oxidized amino acid residue.

8. The method of claim 7 , wherein said oxidized amino acid residue is selected from the group consisting of methionine, tryptophan, histidine, phenylalanine, tyrosine and a combination thereof.

9. The method of claim 8 , wherein said oxidized amino acid residue is histidine.

10. The method of claim 8 , wherein said oxidized amino acid residue is tryptophan.

11. The method of claim 7 , wherein said aflibercept variant comprises a polypeptide having an amino acid sequence selected from the group consisting of: SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71 and combinations thereof.

12. The method of claim 1 , wherein said anti-oxidants are taurine, hypotaurine, glycine, thioctic acid, glutathione, choline, hydrocortisone, Vitamin C, Vitamin E or combinations thereof.

13. The method of claim 1 , wherein the harvest has a color that is:

a. no more yellow-brown than European Color Standard BY2;

b. no more yellow-brown than European Color Standard BY3;

c. no more yellow-brown than European Color Standard BY4;

d. no more yellow-brown than European Color Standard BY5;

e. between European Color Standard BY2 and BY3; or

f. between European Color Standard BY2 and BY4, and

wherein the aflibercept concentration in the harvest is 5.0 g/L.

14. The method of claim 13 , wherein the color of harvest is characterized in the CIE L*, a*, b* color space, where L* is about 70 to about 99, a* is about 0 and b* is about 20 or less than 20 when the concentration of aflibercept is 5.0 g/L.

15. A method of producing aflibercept harvested from a host cell cultured in a chemically defined medium (CDM), comprising:

(a) providing a host cell genetically engineered to express aflibercept;

(b) culturing said host cell in said CDM under conditions suitable in which said host cell expresses said aflibercept wherein the cumulative concentration of nickel in said CDM is about 0.4 μM and one or more of the following:

i. the cumulative concentration of iron in said CDM is less than or equal to 55.0 μM;

ii. the cumulative concentration of copper in said CDM is less than or equal to 0.8 μM;

iii. the cumulative concentration of zinc in said CDM is less than or equal to 56.0 μM;

iv. the cumulative concentration of cysteine in said CDM is less than or equal to 10.0 mM; and

v. said CDM includes anti-oxidants where the cumulative concentration of an antioxidant is about 0.001 mM to about 10.0 mM for any single anti-oxidant; and

(c) harvesting aflibercept produced by said host cell, wherein the color of said harvest is:

a. no more yellow-brown than European Color Standard BY2;

b. no more yellow-brown than European Color Standard BY3;

c. no more yellow-brown than European Color Standard BY4;

d. no more yellow-brown than European Color Standard BY5;

e. between European Color Standard BY2 and BY3; or

f. between European Color Standard BY2 and BY4,

wherein the aflibercept concentration is 5.0 g/L.

16. A method of producing aflibercept harvested from a host cell cultured in a chemically defined medium (CDM), comprising:

(a) culturing said host cell in said CDM under conditions suitable in which said host cell expresses said aflibercept wherein the cumulative concentration of nickel in said CDM is less than or equal to 0.4 μM or about 0.4 μM and one or more of the following:

i. the cumulative concentration of iron in said CDM is less than or equal to 55.0 μM;

ii. the cumulative concentration of copper in said CDM is less than or equal to 0.8 μM;

iii. the cumulative concentration of zinc in said CDM is less than or equal to 56.0 μM;

iv. the cumulative concentration of cysteine in said CDM is less than or equal to 10.0 mM; and

v. said CDM includes anti-oxidants where the cumulative concentration of an antioxidant is about 0.001 mM to about 10.0 mM for any single anti-oxidant; and

(b) harvesting aflibercept produced by said host cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2020
From: LAWRENCE, SHAWN; JOHNSON, AMY; CASEY, MEGHAN; MASTROGIACOMO, JAIMIE; WANG, SHUNHAI; LI, NING
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 054394/0843 →
Continuity (3)
Provisional Application 63065012 · Aug 13, 2020
Provisional Application 62944635 · Dec 6, 2019
Related Publication 20210206832A1 · Jul 8, 2021
Cited By (1)
US 12,319,728